Current Research Trials

• Merck 991

  MK 991 - A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475)Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone More Details...

• Merck 010

  A Phase 3, Randomized Open-label study of Pembrolizumab plus Olaparib versus Abiraterone Acetate or Enzalutamide More Details...

• Merck 641

  A Phase 3 trial of Pembrolizumab and Enzalutamide. More Details...

• Merck 921

  A Phase 3, Randomized, Double-Blind study of Pemrbrolizumab plus Docetaxel plus prednisone versus Placebo plus Docetaxel Plus Prednisone. More Details...

• Genomic Health

  Genomic Health- A Retrospective Multicenter Study to Assess Treatment Decisions and Outcomes for NCCN Favorable Intermediate Risk Patients After Receiving the Oncotype DX Genomic Prostate Score Result More Details...

• CUSP Merck 057

  Merck 057- A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) More Details...

• Laekna LAE201INT2101

  LAE201INT2101- A Phase1/2 Dose-Escalation and Efficacy Study of LAE001/prednisone plus Afuresertib. More Details...

• Myriad URO-012

  URO-012 – A Prospective Registry for Hereditary Cancer Risk Assessment and Genetic Testing. More Details...